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probabilistic sensitivity analysis suggests that at willingness-to-pay threshold of 
£20-£30,000 per quality-adjusted life year, the probability of early treatment being 
cost-effective is 60%. ConClusions: Panretinal photocoagulation administered 
at the severe NPDR stage is likely to be cost-effective. However, given the limita-
tions of the evidence on current treatments, these results to be interpreted with 
caution. A trial of early versus deferred laser therapy is needed to provide better 
data based on modern treatments.
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objeCtives: CUA of cryosurgery, topical treatments (diclofenac 3% 12 weeks, 
imiquimod 3.75% 6 weeks or 5% 4/8 weeks, ingenol mebutate gel (IMG) 0.015%/
head 3 days or 0.05%/body 2 days), and methyl aminolevulinate + photodynamic 
therapy (MAL+PDT) in the treatment of 25cm2 AK-plague affecting any body 
part. Methods: A sequential probabilistic decision-tree with 2-year time-horizon 
was used to assess the cost-utility (incremental cost-effectiveness ratio, ICER) of 
AK-treatments, and to determine the cost-effectiveness acceptability frontier (CEAF) 
and expected value of perfect information per patient (EVPI) from health care payer 
perspective. In the model, the first-line AK-treatment resulted in complete clearance 
(CC) with or without adverse events (AE), non-CC or AK-recurrence. Non-CC AK was 
retreated with PDT and AK-recurrence was retreated with the previous treatment. 
Incident AK-patients (year 2009, n= 3409, organ transplant patients excluded) were 
identified from the Finnish hospital discharge register to assess AK-related 2-year 
secondary health care costs for patients initiating different treatment regimens. 
Other costs included general practitioner, AE-management, and outpatient drugs 
(5/2014 without VAT; other costs in 2013 value). Quality-adjusted life-years (QALY) 
were based on EQ-5D. Results were discounted with 3% annually. Results: The 
mean per patient 2-year QALYs (costs) were 1.519 (€ 727) for IMG 0.015%, 1.518 (€ 887) 
for MAL+PDT, 1.516 (€ 802) for IMG 0.05%, 1.514 (€ 995) for diclofenac, 1.512 (€ 815) for 
imiquimod 3.75%, 1.511 (€ 707) for imiquimod 5%, and 1.507 (€ 1010) for cryosurgery. 
IMG 0.015% had € 2806/QALY gained ICER against imiquimod 5%, and dominated 
other AK-treatments. IMG 0.05% dominated diclofenac, imiquimod 3.75% and 
cryosurgery, and had € 21,550/QALY gained ICER against imiquimod 5%. MAL+PDT 
had € 32,848/QALY gained ICER against IMG 0.05%. Based on the CEAF, IMG 0.015% 
was the optimal treatment when willingness-to-pay/QALY gained exceeded € 2806. 
The EVPI was € 25/€ 81/€ 211 with the willingness-to-pay of € 0/€ 15,000/€ 30,000 per 
QALY gained. ConClusions: IMG 0.015% was the most cost-effective first-line 
AK-treatment.
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objeCtives: To estimate the cost-effectiveness of ranibizumab 0.5mg pro re nata 
(PRN) compared with aflibercept 2mg bi-monthly in the treatment of visual impair-
ment (VI) due to diabetic macular oedema (DMO) taking a UK health care perspec-
tive. Methods: A Markov model previously reviewed by the National Institute for 
Health and Care Excellence (NICE) was used to simulate the long-term outcomes 
and costs (at 2012 price level) of treating DMO. The health states were defined by 
increments of 10 letters in best-corrected visual acuity (BCVA) with a 3-month 
cycle length. Patients could gain (or lose), at most, 2 health states between two 
cycles. A lifetime time horizon was implemented. Future costs and health out-
comes were discounted at 3.5% per annum. Baseline characteristics, ranibizumab 
effectiveness and adverse events were estimated with data from the RESTORE trial 
(36 months). A published network meta-analysis was used to assess the relative 
effectiveness of ranibizumab to aflibercept. Aflibercept injection frequency was 
calculated with VIVID/VISTA phase III trials. Different utilities were used if the 
treated eye was the better or the worse-seeing eye. Results: Ranibizumab mono-
therapy leads to an incremental gain of 0.05 quality-adjusted life-years (QALY) 
(0.04 from the better-seeing eye and 0.01 from the worse-seeing eye) with a cost 
savings of ₤5,841 relative to aflibercept. Therefore, ranibizumab provides greater 
health gains with lower overall costs than aflibercept. Probabilistic sensitivity 
analysis shows that ranibizumab has a 58% probability of being dominant and 
79% probability of being cost effective compared with aflibercept at a willingness-
to-pay threshold of £20 000/QALY. ConClusions: Ranibizumab is dominant over 
aflibercept in the treatment of VI due to DMO.
PSS35
the fUtUre heAlth eConomiC PotentiAl of next GenerAtion 
ArtifiCiAl viSion deviCeS for treAtinG blindneSS in GermAny: An 
eArly CoSt-Utility ASSeSSment
Schwander B.
AHEAD GmbH, Loerrach, Germany
objeCtives: The next generation of artificial vision devices (AVDs), which is cur-
rently tested in clinical trials, has the potential to improve the vision of blind 
patients with retinitis pigmentosa (RP) in a manner that they will be categorized 
as visual impaired but no longer as blind. This unprecedented vision improvement 
will result in a mentionable quality of life gain which poses the question at which 
costs the next generation AVDs are to be regarded as cost-effective. Methods: 
In order to answer this research question a Markov model, with the health states 
blind, visual impaired and death, was developed to simulate and to compare 
the costs and effects of next generation AVDs versus best supportive care (BSC) 
over a lifetime horizon. Health care costs and health utilities for the Markov health 
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objeCtives: To compare ranibizumab with photodynamic therapy (PDT) for 
the treatment of predominantly classic chorodial neovascularization associated 
with age-related macular degeneration (AMD) by means of cost-utility analysis in 
China. Methods: This study compared cost-effectiveness between Ranibizumab 
group (each delivering 0.5 mg of ranibizuamb monthly) and PDT group for the first 
year (short-term) using decision tree model, from third-payer perspective. During 
a 10-year time horizon (long-term), a Markov model was constructed to extrapolate 
effects of treatment beyond clinical trials from a societal perspective (discounted at 
5%). Visual acuity data from the Anti-Vascular Endothelial Growth Factor Antibody 
for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD 
(ANCHOR) trial were applied. Direct-vision-related medical costs were based on 
Clinical Pathway of AMD in China and experts consultation. We performed a lit-
erature review and meta-analysis to estimate the costs related to comorbid states, 
including fall and depression resulting from low vision after suffer from AMD, which 
were rarely inclusive in most previous studies. Informal care costs and utilities data 
were derived from published studies. All costs were adjusted according to 2012 price 
index in China. Probabilistic sensitivity analyses (PSA) were performed to test the 
robustness in structural assumptions and parameter inputs. Cost-effective accepta-
bility curves were performed after a 1000-sample Monte Carlo simulation. Results: 
In short-term model, the incremental cost-effectiveness ratio (ICER) was $81,029/
QALY for ranibizumab compared with PDT. The ICER was reduced to $13,206/QALY 
for a 10-year time frame, when follow-up costs were included. From a societal per-
spective, PSA revealed a 97.75% probability of ranibizuamb being more cost-effective 
than PDT at a threshold of $18,278 per QALY gained (3 times Chinese GDP per capita 
in 2012) in China. ConClusions: Ranibizumab can be a long-term cost-effective 
option for the treatment of AMD compared with PDT from a societal perspective.
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objeCtives: To conduct the cost-utility analysis (CUA) of treatment strategy with 
ranibizumab recommended by the Chinese Clinical Pathway of age-related macu-
lar degeneration (AMD) in China. Methods: Visual acuity data for the as-needed 
dosing regimen with ranibizumab (RBZ-PRN, administrated every month for three 
doses, additional reinjections were determined by physicians’ need) were derived 
from pivotal trials, based on ranibizumab dose of 0.5 mg. Decision tree model and 
Markov model were developed to estimate RBZ-PRN compared with best supportive 
care (BSC) for short and long term. The first year decision tree model from a third-
payer perspective was performed to estimate CUA in short-term. Then a 10-year 
Markov model from a societal perspective were constructed (discounted at 5%) in 
long-term CUA estimation. Resource utilization was obtained from official recom-
mendations in China. The costs of low-vision related disease were extrapolated from 
meta-analysis. Informal care costs and utility values were estimated by published 
studies. The uncertainty was identified in a one-way sensitivity analysis and proba-
bilistic sensitivity analysis (PSA). Cost-effective acceptability curves were obtained 
by a Monte Carlo approach with 1000 repetitions. Results: For RBZ-PRN compared 
with BSC, the incremental cost-effectiveness ratios (ICER) ranged from $90,546/QALY 
for the 1-year time frame to $9,787/QALY for the 10-year time horizon. As indicated 
in the PSA, RBZ-PRN was the optimal strategy in 100% of cases below the willingness 
to pay threshold of $18,278 per QALY gained (3 times Chinese GDP per capita in 2012) 
for the 10-year model. ConClusions: When administered as needed, ranibizumab 
is cost-effective compared with BSC from a societal perspective. In China’s current 
clinical practice, this can be a useful tip for decision-makers who should consider 
cost-effective issues for the treatment of wet-AMD.
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objeCtives: Diabetic retinopathy (DR) is a leading cause of sight loss in people 
of working age. There have been recent developments in laser photocoagulation 
techniques, along with anti-vascular endothelial growth factor drugs for the 
treatment of severe non-proliferative and proliferative DR. The aim of the study 
was to evaluate the cost-effectiveness of panretinal photocoagulation admin-
istered at the severe non-proliferative diabetic retinopathy (NPDR) stage (early 
treatment), compared with waiting until high-risk proliferative (HR-PDR) char-
acteristics (deferred treatment) developed. Methods: A Markov model with a 
30-year time horizon was developed, with clinical pathway options for patients 
presenting with moderate NPDR through to irreversible-severe vision loss and 
blindness (and to death). Once patients entered a post-treatment health state 
they can progress to more severe health states, regress back to earlier stages of the 
disease, persist where they are, or die. NHS and personal social services perspec-
tive was adopted. Transition probabilities were based mainly on data derived from 
the Early Treatment Diabetic Retinopathy Study. Health state utilities, costs and 
complications were based on information from the literature, supplemented by 
expert opinion. Costs and outcomes were discounted at 3.5%. Both deterministic 
and probabilistic sensitivity analyses were conducted. Results: Administering 
panretinal photocoagulation at the severe NPDR stage was more effective and 
less costly than waiting until HR-PDR developed. Sensitivity analyses gave similar 
results, with early treatment continuing to dominate deferred treatment. The 
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objeCtives: Although several studies reported patients with chronic disease were 
found to have lower medication adherence and higher discontinuation rates as 
disease duration increased, it is still not evident in glaucoma patients. With this 
perspective, this study was designed to assess the association of disease dura-
tion with medication adherence and discontinuation in glaucoma patients in 
Korea. Methods: It was a cross-sectional, multi-centered and observational study 
where glaucoma outpatients with less than two years of drug use were recruited at 
15 eye clinics from March to November 2013. All patients completed a self-admin-
istered questionnaire asking about their daily use of glaucoma medications to esti-
mate adherence and discontinuation. Medication adherence and discontinuation 
were defined as patients administering the drug for ≥ 80% of prescribed days and if 
patients stopped taking medication for 7 consecutive days respectively. Results: 
A total of 1,050 glaucoma patients were enrolled in the study. Of the total, 14.4% 
showed to be non-adherent to their glaucoma therapy and 7.5% had the experi-
ence of medication discontinuation. All patients were categorized into 3 groups 
according to disease duration: group A ≤ 1 year (n= 600,57.1%), B > 1 year and ≤ 2 
years (n= 415,39.5%), and C > 2 years (n= 35,3. 3%). The patients of group A with 
the disease duration ≤ 1 year were likely to be non-adherent to glaucoma therapy 
compared to those with longer disease duration. (A: 84.9% vs. B: 86% vs. C: 100%, 
p= . 045) Highest discontinuation rate was found in group B with the disease duration 
bewteen 1 and 2 years. (A: 6.7% vs. B: 8.9% vs. C: 5.7%, P= . 380) ConClusions: The 
study results highlight more attention should be paid to the patients who newly 
started glaucoma therapy because in the patients with less than 2 years of disease 
duration the adherence was low and the discontinuation rate was high.
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objeCtives: To compare a newly developed condition-specific utility index (CSUI), 
the Pressure Ulcer Quality of Life Utility Index (PUQoL-UI) with generic and directly 
elicited TTO values. Methods: The PUQoL-UI was completed by a group of patients 
(n= 100) in England with pressure ulcers (PUs) along with the EQ-5D and own health 
TTO. The discriminatory power of the utility measures was assessed across PU 
grade and health and PU severity ratings. Multivariate regression was conducted 
to explore determinants of utility values. Results: The mean sample age was 77.2 
years (range 22.7-101.7), 49% were female and 50% wheelchair users. Mean (SDs) 
utility for superficial PUs (grades 1-2) were 0.72 (0.17), 0.70 (0.35) and 0.24 (0.16) and 
for severe PUs (grades 3-4) 0.67 (0.17), 0.65 (0.35) and 0.15 (0.38) for the PUQoL-UI, TTO 
and EQ-5D, respectively. Mean (SDs) utility by self-reported PU severity was: [Mild] 
0.78 (0.16), 0.66 (0.35), 0.29 (0.36); [Moderate] 0.72 (0.17), 0.63 (0.38), 0.25 (0.34); [Severe] 
0.58 (0.17), 0.70 (0.33), 0.04 (0.40) for the PUQoL-UI, TTO and EQ-5D, respectively. 
Regression analyses indicated both EQ-5D and PUQoL-UI values were explained by 
perceived severity and general health ratings but not demographics or PU grade. 
Duration and body part affected were additional significant explanatory factors of 
the EQ-5D while wheelchair use approached significance. ConClusions: Values 
were much lower for the EQ-5D than the other assessments which may be partly 
explained by the range in EQ-5D and partly due to background mobility issues being 
captured. The PUQoL-UI appears to have good discriminatory power and is recom-
mended for use in trials of PU interventions. The utilities presented here will be use-
ful for decision-analytic models that incorporate PU impact. Probabilistic sensitivity 
analyses including the PUQoL-UI will likely generate lower levels of uncertainty than 
the EQ-5D due to the smaller SDs for health states.
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objeCtives: To obtain utility estimates suitable for use in economic models for 
chronic spontaneous (idiopathic) urticaria (CSU). Methods: Patient-level data from 
three randomised clinical trials: ASTERIA I, ASTERIA II, and GLACIAL were analysed. 
Health states were derived from Urticaria Activity Score (UAS7), a patient-completed 
diary of signs and symptoms which calculates an average daily score over 7 days. 
Higher score means more severe symptoms. UAS7 scores for the health states were: 
Urticaria-free: 0; Well-controlled urticaria: 1-6; Mild urticaria: 7-15; Moderate urti-
caria: 16-27; Severe urticaria: 28-42. Mean EQ-5D utilities were calculated for each 
health state. Individual trial analyses showed inconsistent utilities across the UAS7 
health states due to small subsample sizes. A mixed model was used to predict 
EQ-5D according to UAS7 health states in a pooled dataset containing all treatment 
arms and time-points from the three trials. The predictor variable was UAS7 health 
state and the dependent variable was EQ-5D utility. Fixed/random effects for trial 
and patient were included and the following covariates: UAS7 health state at base-
line (Moderate or Severe), presence of angioedema at baseline and during follow-up, 
duration of CSU, number of previous CSU medications, and gender of the patient. 
A parsimonious model was selected using the approach of backwards elimination; 
UAS7 health state was forced into the model. The validity of pooling trials was con-
sidered through visual comparisons and interaction terms. Results: There was a 
consistent improvement in EQ-5D utilities as severity of urticaria improved. Mean 
utilities at Week 12 ranged from 0.712 in patients with severe urticaria to 0.897 in 
patients who were urticaria-free. Sensitivity analysis confirmed the robustness of 
results. ConClusions: The results suggest that EQ-5D utility score increased with 
decreasing severity of urticaria. EQ-5D utility scores allow the comparison of HRQoL 
across diseases by calculating QALYs in economic models.
states were determined on the basis of published literature. For next generation 
AVDs, which are currently tested in clinical trials, various possible effect and 
pricing scenarios have been simulated. Results: Applying the base case settings 
resulted in incremental costs of € 107,925, in 2.03 incremental quality-adjusted 
life years (QALYs) and in a cost-effectiveness ratio of € 53,165 per QALY gained. 
Probabilistic and deterministic sensitivity analyses as well as scenario analyses 
for the effect size and the AVD costs were performed in order to investigate the 
robustness of results. In these analyses a strong variation of the cost-effectiveness 
results was obtained ranging from € 23,512 (best case) to € 176,958 (worst case) 
per QALY gained. ConClusions: The innovative nature, the high unmet medi-
cal need and the expected unprecedented efficacy of next generation AVDs will 
highly likely lead to the case that even relatively high incremental cost effective-
ness ratios, that have been obtained when simulating various effect and pric-
ing scenarios, will be regarded as acceptable from a German health care payer 
perspective.
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objeCtives: Intraoperative threshold measurement is a part of the cochlear 
implantation procedure and in the current setting conducted by the clinicians 
with a standard set-up. The newly released CR220 Intraoperative Remote Assistant 
is a handheld device and can also be used by someone already in the operating 
theatre (OT). The aim of this study was to compare measurement time with the 
new CR220 and standard set-up and to investigate from the clinic’s perspective any 
cost-savings created as a result of time-savings with the new device. Methods: 
Stages of the measurement process are identified and the time is measured 
for each stage during 113 patients’ implantation procedure. A literature review 
was conducted to identify the reimbursement level of this process in order to 
translate any time-savings to cost savings. Results: When the clinician trav-
els to the OT, the mean time spent per procedure with CR220 is 8.4% less than 
the computer set-up (163.7 minutes vs 149.9 minutes). If the measurement is 
conducted by someone already in the OR, the measurement time is reduced by 
95.5% with the CR220 (163.7 minutes vs 7.3 min). Literature review revealed that 
the fee for measurement as $18.99-22.57 per 15 minutes in the US setting and 
in most of the other settings this procedure is not reimbursed separately but 
covered under cochlear implantation. ConClusions: The analysis showed that 
considerable time is spent for the clinician to travel to OT and waiting in the OT. 
This “unproductive” time is not only wasteful, but also means the clinician is not 
available in the clinic seeing patients where their expert skills are of most value. 
Moreover the clinic is either underpaid or is not paid at all for this expertise and 
time demanding process. The new CR220 gives clinics the opportunity to allocate 
their limited resources efficiently.
SenSory SyStemS diSorderS – Patient-reported outcomes & Patient  
Preference Studies
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objeCtives: There are few studies combining dose regimen in routine clinical 
practice, drug survival rates and costs of biological agents for the treatment of 
naïve patients with moderate-to-severe psoriasis in the clinical practice. To assess 
the dose regimen in routine clinical practice, drug survival rate (persistence rate) 
and efficiency (cost per persistence) for etanercept (ETN), adalimumab (ADA) and 
ustekinumab (UST) in a real practice clinical setting. Methods: A retrospective 
study on psoriasis patients aged ≥ 18 years, naïve to a biological agent and a mini-
mum of 6 months of treatment was performed in 5 public health system hospitals 
in the Balearic Islands (Spain) for the period from January 1st 2010 to December 31st 
2013. The recorded variables were: sex, weight, age, indication (psoriasis or psoriatic 
arthritis), discontinuation reason and pharmacy dispensation records. Costs were 
based on the average wholesale price, estimating annual cost according to the first 
treatment received. Persistence rates were reckoned taking into account the cur-
rent total days of therapy comparing posology with pharmacy supplied dose, and 
were estimated using the method of Kaplan-Meier. Results: During the study 
period a cohort of 112 psoriatic patients (57% men) were evaluated: 37 patients 
with ADA (81 kg, 51 years, 27; mean weight, mean age, and prevalence of psoriatic 
arthritis respectively), 34 with ETN (82 kg, 52 years, 25%) and 41 with UST (76 kg, 43 
years, 19%). The persistence rate at 2 years was, 48%, 62% and 81% and the cost per 
persistence at 2 years was 52.961 € , 40.160 € , and 30.657 € (for ADA, ETN and UST 
respectively). ConClusions: UST showed better overall drug survival compared 
to ETN and ADA. UST has been the most efficient alternative for the treatment of 
naïve patients and has shown the least budget-impact per persistent-patient at 2 
years analysis.
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